UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

SCHEDULE 13G

Under the Securities Exchange Act of 1934

(Amendment No.    )*

IDI, Inc.

(Name of Issuer)

Common Stock, $0.0005 par value per share

(Title of Class of Securities)

44938L108

(CUSIP Number)

July 23, 2015

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

Page 2 of 8

Page 3 of 8

Page 4 of 8

(a) Name of Issuer

IDI, Inc. (the “Issuer”)

(b) Address of Issuer’s Principal Executive Offices

2650 North Military Trail, Suite 300

Boca Raton, FL 33431

(a) Name of Person Filing

(b) Address of Principal Business Office or, if none, Residence

(c) Citizenship

This Schedule 13G is being filed on behalf of (i) Mitchell P. Kopin, an individual who is a citizen of the United States of America (“Mr. Kopin”), (ii) Daniel B. Asher, an individual who is a citizen of the United States of America (“Mr. Asher”) and (iii) Intracoastal Capital LLC, a Delaware limited liability company (“Intracoastal” and together with Mr. Kopin and Mr. Asher, collectively the “Reporting Persons”).

The Reporting Persons have entered into a Joint Filing Agreement, a copy of which is filed with this Schedule 13G as Exhibit 1, pursuant to which the Reporting Persons have agreed to file this Schedule 13G jointly in accordance with the provisions of Rule 13d-1(k) of the Securities Exchange Act of 1934, as amended.

The principal business office of Mr. Kopin and Intracoastal is 245 Palm Trail, Delray Beach, Florida 33483.

The principal business office of Mr. Asher is 111 W. Jackson Boulevard, Suite 2000, Chicago, Illinois 60604.

(d) Title of Class of Securities

Common stock, $0.0005 par value per share, of the Issuer (the “Common Stock”).

(e) CUSIP Number

44938L108

Not applicable.

(a) and (b):

(i) Immediately following the execution of the Securities Purchase Agreement with the Issuer on July 23, 2015 (the “SPA”) (as disclosed in the Form 8-K filed by the Issuer with the Securities and Exchange Commission on July 28, 2015), each of the Reporting Persons may be deemed to beneficially own 1,280,410 shares of Common Stock, and all such shares of Common Stock in the aggregate represent beneficial ownership of approximately 8.4% of the Common Stock, based on (1) 13,958,076 shares of Common Stock outstanding immediately prior to the execution of the SPA as reported by the Issuer plus (2) 1,280,410 shares of Common Stock that was to be issued to Intracoastal at the closing of the transaction contemplated by the SPA. The foregoing excludes 640,205 shares of Common Stock issuable upon exercise of a warrant that was to be issued to Intracoastal at the closing of the transaction contemplated by the SPA (the “Warrant”) because the Warrant is not exercisable until on or after January 23, 2016

Page 5 of 8

(and the Warrant contains a blocker provision under which the holder thereof does not have the right to exercise the Warrant to the extent that such exercise would result in beneficial ownership by the holder thereof (together with the holder’s affiliates, and any other persons acting as a group together with the holder or any of the holder’s affiliates) of more than 4.99% of the Common Stock). Without such blocker provision (and assuming the Warrant is currently exercisable), each of the Reporting Persons may be deemed to beneficially own 1,920,615 shares of Common Stock

(ii) As of the close of business on July 30, 2015, each of the Reporting Persons may be deemed to beneficially own 1,243,803 shares of Common Stock, and all such shares of Common Stock in the aggregate represent beneficial ownership of approximately 8.2% of the Common Stock, based on (1) 13,958,076 shares of Common Stock outstanding immediately prior to the execution of the SPA as reported by the Issuer plus (2) 1,280,410 shares of Common Stock issued at the closing of the transaction contemplated by the SPA. The foregoing excludes 640,205 shares of Common Stock issuable upon exercise of the Warrant because the Warrant is not exercisable until on or after January 23, 2016 (and the Warrant contains a blocker provision under which the holder thereof does not have the right to exercise the Warrant to the extent that such exercise would result in beneficial ownership by the holder thereof (together with the holder’s affiliates, and any other persons acting as a group together with the holder or any of the holder’s affiliates) of more than 4.99% of the Common Stock). Without such blocker provision (and assuming the Warrant is currently exercisable), each of the Reporting Persons may be deemed to beneficially own 1,884,008 shares of Common Stock

(c) Number of shares as to which each Reporting Person has:

(i) Sole power to vote or to direct the vote: 0.

(ii) Shared power to vote or to direct the vote: 1,243,803.

(iii) Sole power to dispose or to direct the disposition of 0.

(iv) Shared power to dispose or to direct the disposition of 1,243,803.

Not applicable.

Not applicable.

Not applicable.

Not applicable.

Not applicable.

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under §240.14a-11.

Page 6 of 8

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Date: July 30, 2015

Page 7 of 8